Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock

Journey Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 14,905 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.01, for a total transaction of $74,674.05. Following the completion of the transaction, the chief executive officer now directly owns 2,052,418 shares in the company, valued at $10,282,614.18. This trade represents a 0.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Claude Maraoui also recently made the following trade(s):

• On Tuesday, March 11th, Claude Maraoui sold 49,271 shares of Journey Medical stock. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71.
• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The stock was sold at an average price of $5.19, for a total value of $122,006.52.

Journey Medical Stock Performance

NASDAQ:DERM traded down $0.09 during trading hours on Friday, reaching $5.25. The stock had a trading volume of 17,087 shares, compared to its average volume of 93,160. Journey Medical Co. has a 12-month low of $2.85 and a 12-month high of $6.89. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The stock has a 50 day simple moving average of $4.68 and a 200 day simple moving average of $5.10. The stock has a market cap of $109.67 million, a P/E ratio of -5.59 and a beta of 0.97.

Remove Ads

Institutional Trading of Journey Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of DERM. Cetera Investment Advisers grew its holdings in shares of Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock worth $54,000 after purchasing an additional 2,478 shares in the last quarter. PVG Asset Management Corp grew its stake in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after buying an additional 9,005 shares in the last quarter. Nwam LLC purchased a new stake in shares of Journey Medical during the 3rd quarter valued at $59,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Journey Medical during the 3rd quarter worth $66,000. Finally, Geode Capital Management LLC increased its stake in Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after acquiring an additional 12,882 shares during the last quarter. Institutional investors own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.